Efficacy of a negative conversion trial and subsequent living donor kidney transplant outcome in recipients with a positive lymphocyte crossmatch

Nephron Clin Pract. 2009;111(1):c49-54. doi: 10.1159/000178979. Epub 2008 Dec 3.

Abstract

Background: Patients with a positive lymphocyte crossmatch (LCX) do not undergo kidney transplantation. In such patients, a negative conversion protocol consisting of intravenous immunoglobulin (IVIG), plasmapheresis, and potent immunosuppressant is one of the options for transplantation.

Methods: 14 patients who showed a positive LCX with living donors underwent a trial of negative conversion between January 2002 and July 2007. Plasmapheresis was performed every other day, up to 6 times maximum. IVIG was infused after plasmapheresis, with a total dose of 500 mg/kg divided over 6 days. Kidney transplantation was performed immediately after negative conversion. Anti-thymocyte globulin (ATG) or OKT3 induction therapy was used with the combination of tacrolimus, mycophenolate mofetil, and prednisone in the perioperative period.

Results: Negative conversion of LCX was achieved in 13 of 14 patients (92.9%). Transplantations were performed successfully in these 13 patients without hyperacute rejection. Four recipients developed acute rejection, which was well controlled by steroid pulse therapy. During the follow-up periods of 45.4 +/- 22.0 months, all recipients except 1 showed excellent graft function.

Conclusion: Selected patients with a positive LCX can undergo successful transplantation using plasmapheresis, IVIG, and potent immunosuppressants. Recipients with negative conversion of LCX showed acceptable posttransplant results.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use
  • B-Lymphocytes / immunology
  • Female
  • Graft Rejection / etiology
  • Graft Rejection / prevention & control
  • Histocompatibility Testing*
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunosuppression Therapy / methods*
  • Immunosuppressive Agents / therapeutic use*
  • Isoantibodies / blood*
  • Kidney Transplantation / immunology*
  • Living Donors*
  • Male
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Plasmapheresis*
  • Prednisone / administration & dosage
  • Prednisone / therapeutic use
  • Premedication
  • Preoperative Care / methods*
  • Reoperation
  • T-Lymphocytes / immunology
  • Tacrolimus / administration & dosage
  • Tacrolimus / therapeutic use
  • Transplantation, Homologous / immunology*
  • Treatment Outcome

Substances

  • Antilymphocyte Serum
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Isoantibodies
  • Muromonab-CD3
  • Mycophenolic Acid
  • Prednisone
  • Tacrolimus